Titre : Fondaparinux

Fondaparinux : Questions médicales fréquentes

Questions fréquentes et termes MeSH associés

Général 1

#1

Erreur lors de la génération.

Veuillez réessayer ultérieurement.
Fondaparinux
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Fondaparinux : Questions médicales les plus fréquentes", "headline": "Fondaparinux : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Fondaparinux : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-27", "dateModified": "2026-04-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Fondaparinux" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Oligosaccharides", "url": "https://questionsmedicales.fr/mesh/D009844", "about": { "@type": "MedicalCondition", "name": "Oligosaccharides", "code": { "@type": "MedicalCode", "code": "D009844", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D09.698.629" } } }, "about": { "@type": "MedicalCondition", "name": "Fondaparinux", "alternateName": "Fondaparinux", "code": { "@type": "MedicalCode", "code": "D000077425", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mohammed Yunus Khan", "url": "https://questionsmedicales.fr/author/Mohammed%20Yunus%20Khan", "affiliation": { "@type": "Organization", "name": "Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad 500018, India. doctorkhan26@gmail.com." } }, { "@type": "Person", "name": "Kumar Gaurav", "url": "https://questionsmedicales.fr/author/Kumar%20Gaurav", "affiliation": { "@type": "Organization", "name": "Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad 500018, India." } }, { "@type": "Person", "name": "Kevin Pagel", "url": "https://questionsmedicales.fr/author/Kevin%20Pagel", "affiliation": { "@type": "Organization", "name": "Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany." } }, { "@type": "Person", "name": "Jan Miroslav Hartinger", "url": "https://questionsmedicales.fr/author/Jan%20Miroslav%20Hartinger", "affiliation": { "@type": "Organization", "name": "Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic." } }, { "@type": "Person", "name": "Ondřej Slanař", "url": "https://questionsmedicales.fr/author/Ond%C5%99ej%20Slana%C5%99", "affiliation": { "@type": "Organization", "name": "Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Fondaparinux versus Enoxaparin in the Treatment of Obese Patients with Acute Coronary Syndrome.", "datePublished": "2024-09-23", "url": "https://questionsmedicales.fr/article/39319877", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.36660/abc.20230793" } }, { "@type": "ScholarlyArticle", "name": "Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China.", "datePublished": "2024-09-01", "url": "https://questionsmedicales.fr/article/39240728", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/FJC.0000000000001596" } }, { "@type": "ScholarlyArticle", "name": "Synthesis of Anticoagulant Pentasaccharide Fondaparinux via 3,5-Dimethyl-4-(2'-phenylethynylphenyl)phenyl Glycosides.", "datePublished": "2023-11-20", "url": "https://questionsmedicales.fr/article/37983186", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.orglett.3c03484" } }, { "@type": "ScholarlyArticle", "name": "Monitoring the appropriate prescription of low molecular weight heparins and Fondaparinux through administrative data. A retrospective observational study in the Tuscany region.", "datePublished": "2023-09-14", "url": "https://questionsmedicales.fr/article/37708187", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0291628" } }, { "@type": "ScholarlyArticle", "name": "Comparison of the efficacy of low-molecular-weight heparin and fondaparinux sodium after total knee arthroplasty: a retrospective cohort study.", "datePublished": "2023-07-04", "url": "https://questionsmedicales.fr/article/37403062", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12891-023-06674-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Glucides", "item": "https://questionsmedicales.fr/mesh/D002241" }, { "@type": "ListItem", "position": 3, "name": "Polyosides", "item": "https://questionsmedicales.fr/mesh/D011134" }, { "@type": "ListItem", "position": 4, "name": "Oligosaccharides", "item": "https://questionsmedicales.fr/mesh/D009844" }, { "@type": "ListItem", "position": 5, "name": "Fondaparinux", "item": "https://questionsmedicales.fr/mesh/D000077425" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Fondaparinux - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Fondaparinux", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2026-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Général", "headline": "Général sur Fondaparinux", "description": "Erreur lors de la génération.", "url": "https://questionsmedicales.fr/mesh/D000077425#section-général" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Erreur lors de la génération.", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Veuillez réessayer ultérieurement." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 16/04/2026

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Kevin Pagel

2 publications dans cette catégorie

Affiliations :
  • Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.
  • Fritz Haber Institute of the Max Planck Society, 14195 Berlin, Germany.
Publications dans "Fondaparinux" :

Jan Miroslav Hartinger

2 publications dans cette catégorie

Affiliations :
  • Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Ondřej Slanař

2 publications dans cette catégorie

Affiliations :
  • Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Vincenzo Russo

2 publications dans cette catégorie

Affiliations :
  • Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli"-Monaldi Hospital, Naples, Italy.

Giuseppe Cardillo

2 publications dans cette catégorie

Affiliations :
  • Advanced Biochemistry Unit Medylab Institute, Lusciano (CE), Italy.

Giuseppe Vito Viggiano

2 publications dans cette catégorie

Affiliations :
  • Emergency Medicine Unit, Marazzini Hospital, Modena, Italy.

Sara Mangiacapra

2 publications dans cette catégorie

Affiliations :
  • Internal Medicine Unit, Moscati Hospital, Avellino, Italy.

Antonella Cavalli

2 publications dans cette catégorie

Affiliations :
  • Internal Medicine Unit, Frangipane Hospital, Ariano Irpino, Italy.

Andrea Fontanella

2 publications dans cette catégorie

Affiliations :
  • Internal Medicine Unit, Fatebenefratelli Hospital, Naples, Italy; and.

Federica Agrusta

2 publications dans cette catégorie

Affiliations :
  • Emergency Medicine Unit, Marazzini Hospital, Modena, Italy.

Annamaria Bellizzi

2 publications dans cette catégorie

Affiliations :
  • Internal Medicine Unit, Frangipane Hospital, Ariano Irpino, Italy.

Maria Amitrano

2 publications dans cette catégorie

Affiliations :
  • Internal Medicine Unit, Moscati Hospital, Avellino, Italy.

Mariateresa Iannuzzo

2 publications dans cette catégorie

Affiliations :
  • Internal Medicine Unit, Fatebenefratelli Hospital, Naples, Italy; and.

Corrado Lodigiani

2 publications dans cette catégorie

Affiliations :
  • Thrombosis and Hemorragic Center, Humanitas Research Hospital and University, Rozzano, Italy.

Pierpaolo Di Micco

2 publications dans cette catégorie

Affiliations :
  • Internal Medicine Unit, Fatebenefratelli Hospital, Naples, Italy; and.

Lei Wang

2 publications dans cette catégorie

Affiliations :
  • Department of Medical Oncology, The Afflicted Bozhou Hospital of Anhui Medical University, Bozhou, China.

Leonardo De Luca

2 publications dans cette catégorie

Affiliations :
  • Department of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy. Electronic address: leo.deluca@libero.it.

Massimo Uguccioni

2 publications dans cette catégorie

Affiliations :
  • Department of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.

Sources (23 au total)

Fondaparinux versus Enoxaparin in the Treatment of Obese Patients with Acute Coronary Syndrome.

Fondaparinux is an effective and safe anticoagulant in the treatment of acute coronary syndromes (ACS). However, due to the low representation of obese individuals in clinical trials, the effects of a... To compare Fondaparinux to Enoxaparin in the treatment of obese patients with ACS.... This is a retrospective cohort study, including obese individuals (BMI ≥ 30 Kg/m2) admitted with non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina (UA) and treated with Fondap... A total of 367 obese patients with NSTEMI or UA were included, of whom 258 used Fondaparinux and 109 used Enoxaparin. Mean age was 64 ± 12 years, and 52.9% were male. The prevalence of diabetes, hyper... In a sample of obese patients with NSTEMI or UA, there was no difference in the occurrence of the composite outcome (death, stroke, reinfarction, major bleeding) between patients who used Fondaparinux...

Monitoring the appropriate prescription of low molecular weight heparins and Fondaparinux through administrative data. A retrospective observational study in the Tuscany region.

Low Molecular Weight Heparins (LMWHs) and Fondaparinux have been widely used as anticoagulants. Mass prescription may lead to prescriptive inappropriateness, which causes Heparin-induced thrombocytope... The study investigates the appropriate prescription of LMWHs and Fondaparinux in Tuscany. We aim to validate the crude measure of prescription appropriateness of the Key Performance Indicator (KPI) "P... To compare a crude KPI based only on drug consumption with a refined KPI based on exclusions listed in the clinical guidelines, a retrospective observational cohort study was carried out, using the RE... 208,717 LMWH and Fondaparinux users are identified, of which 103,299 fall within the study's inclusion criteria. 16,817 (16%) of LMWHs and Fondaparinux users are classified as high consumption. The re... Although the crude KPI is less refined and detailed than the adjusted indicator computed by our study, it has proven capable to provide an accurate snapshot of the use of these drugs across the region...

Comparison of the efficacy of low-molecular-weight heparin and fondaparinux sodium after total knee arthroplasty: a retrospective cohort study.

Low-molecular-weight heparin (LMWH) and fondaparinux sodium (FPX) are routinely used to prevent deep vein thrombosis (DVT) after total knee arthroplasty (TKA). In this study, we compared the effects o... Clinical data of patients who underwent unilateral TKA for unicompartmental knee osteoarthritis at the Ningxia Medical University General Hospital between September 2021 and June 2022 were retrospecti... Intergroup differences in d-dimer or fibrinogen (FBG) levels before and 1 or 3 days after surgery were not significant (all p > 0.05); within-group pairwise comparisons indicated significant differenc... Both LMWH and FPX can effectively prevent DVT after TKA. There are some suggestive signals that FPX may have more beneficial pharmacological effects and clinical significance, while LMWH is cheaper an...

Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: A meta-analysis.

Current opinion on the superiority of fondaparinux versus low molecular-weight heparin (LMWH) in treating recurrent miscarriage is controversial. This meta-analysis aimed to comprehensively compare th... EMBASE, PubMed, Cochrane, China National Knowledge Internet (CNKI), Wanfang Database, and China Science and Technology Journal Database (CQVIP) databases were searched for articles reporting fondapari... Six eligible studies (4 observational studies and 2 RCTs) with 321 patients receiving fondaparinux and 546 patients receiving LMWH were enrolled. Live birth (relative risks (RR) = 1.05, 95% confidence... Fondaparinux is attributable to fewer adverse events and similar pregnancy outcomes compared with LMWH in patients with recurrent miscarriage....

Comparison of efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism in lower extremities after total hip arthroplasty and total knee arthroplasty: a retrospective study of 592 patients.

To compare the efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism (DVT) in lower extremities after total hip arthroplasty (THA) and total knee arthroplasty (TKA... A total of 592 patients were enrolled in the study. Clinical data of patients who underwent total hip arthroplasty (THA) and total knee arthroplasty (TKA) in our hospital from December 2021 to Septemb... The prevalence of DVT in the nadroparin group and the fondaparinux sodium group was 8.3% (23/278) and 15.0% (47/314), respectively(p = 0.012). Statistical analysis showed that nadroparin group showed ... Nadroparin may have an advantage over fondaparinux sodium in preventing DVT in lower extremities after THA and TKA....

The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis.

Venous thromboembolism (VTE) is a major complication of trauma. Currently, there are few studies summarising the evidence for prophylaxis in trauma settings. This review provides evidence for the use ... A PRISMA-compliant review was conducted from Sep 2021 to June 2023, using Embase, Medline and Google Scholar. The inclusion criteria were: randomized-controlled trials (RCTs) in English published afte... Of the 7,948 search results, 23 studies with a total of 21,312 participants fulfilled screening criteria, which included orthopaedic, spine, solid organ, brain, spinal cord, and multi-region trauma. O... Enoxaparin and fondaparinux are safe and effective options for VTE prevention in trauma patients, with fondaparinux being a cheaper and easier administration option between the two. Inconclusive resul...